Glutamine metabolism is reprogrammed during tumorigenesis and has been investigated as a promising target for cancer therapy. However, efforts to drug this process are confounded by the intrinsic metabolic heterogeneity and flexibility of tumors, as well as the risk of adverse effects on the anticancer immune response. Recent research has yielded important insights into the mechanisms that determine the tumor and the host immune responses to pharmacological perturbation of glutamine metabolism. Here, we discuss these findings and suggest that, collectively, they point toward patient stratification and drug combination strategies to maximize the efficacy of glutamine metabolism inhibitors as cancer therapeutics.

谷氨酰胺代谢在肿瘤发生过程中被重新编程，并已被研究为癌症治疗的有希望的靶点。然而，对这一过程进行药物治疗的努力被肿瘤固有的代谢异质性和灵活性以及对抗癌免疫反应产生不利影响的风险所混淆。最近的研究对决定肿瘤和宿主对谷氨酰胺代谢药理学扰动的免疫反应的机制产生了重要的见解。在这里，我们讨论了这些发现，并建议它们共同指向患者分层和药物组合策略，以最大限度地发挥谷氨酰胺代谢抑制剂作为癌症治疗剂的功效。